Adalimumab Clearance, rather than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically.
Emily K WrightMaria ChaparroPaolo GionchettiAmy L HamiltonJulien SchulbergFrancisco Javier García-AlonsoMaria Chiara ValeriiFernando RizzelloPeter De CruzJohn C PanettaAnnelie Everts-van der WindMichael A KammThierry DervieuxPublished in: Journal of Crohn's & colitis (2023)
Lower ADA Clearance is associated with an improved clinical outcome for patients with Crohn's disease and may be a superior pharmacokinetic measure than concentration.